Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Canadian Journal of Gastroenterology

Volumn 26, Issue 6, 2012, Pages 353-357

  Beaton, Melanie D ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Fibrosis; Hepatic steatosis; Metabolic syndrome; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADALIMUMAB; ALPHA TOCOPHEROL; BETAINE; CERTOLIZUMAB PEGOL; EXENDIN 4; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LIRAGLUTIDE; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SILYMARIN; SITAGLIPTIN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; VILDAGLIPTIN;

BARIATRIC SURGERY; DIET; HUMAN; LEG EDEMA; LIFESTYLE MODIFICATION; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 84862636851     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/725468     Document Type: Review

References (77)

1. Alfire ME, Treem WR. Nonalcoholic fatty liver disease. Pediatr Ann 2006;35:290-4, 7-9.
2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004;40:1387-95.
3. Improving the Health of Canadians, Canadian Population Health Initiative, Canadian Institute for Health Information, 2004.
4. McCullough AJ. The epidemiology and risk factors for NASH. In: Farrell CG, George J, de la M Hall P, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden: Blackwell Publishing; 2005:23-37.
5. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970;3:371-407.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
7. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-55.
8. Dunn W, Xu R, Winard DL, et al. Suspected nonalcoholic fatty liver diseases and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-71.
9. Adams LA, Harmsen S, St Sauver JL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am J Gastroenterol 2010;105:1567-73.
10. Hertz RP, Unger AN, McDonald M, Lustik MB, Biddulph-Krentar J. The impact of obesity on work limitations and cardiovascular risk factors in the U.S. workforce. J Occup Environ Med 2004;46:1196-203.
11. Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology 2008;134:85-94.
12. Choi SY, Kim D, Kim HJ, et al. The relation between nonalcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009;104:1953-60.
13. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009;(8 Suppl 1):S40-3.
14. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.
15. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-71.
16. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5
17. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
18. Dixon JB, Bhathal PS, Hughes NR et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647.
19. Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961-71.
20. Kistler KD, Brunt EM, Clark JM et al. Physical activitity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106:460-8.
21. Centis E, Marzocchi R, Di Domizio S et al. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 2010;28:267-73.
22. Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007;CK005166.
23. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
24. Loomba R, Lutchman G, Kleiner D, et al. Pilot study of metformin in patients with nonalcoholic steatohepatitis. Hepatology 2006;44:260A (Abst).
25. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
26. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011;305:1659-68.
27. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
28. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo controlled Fatty-Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterol 2008;135:100-10.
29. Torres DM, Jones FJ, Williams CD, et al. The effect of 48 weeks of rosiglitazone alone versus combination rosiglitazone and metformin (Avandamet) versus combination rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis. Hepatology 2009;50:390A (Abst).
30. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23.
31. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with non-alcoholic steatohepatitis. Hepatology 2007;46:424-9.
32. Gastaldelli A, Harrison SA, Belfort R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of NASH patients. Hepatology 2009;50:1087-93.
33. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
34. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
35. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocr Disord 2008;8:14.
36. Migoya EM, Stevens H, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-70.
37. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-7.
38. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors an hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86.
39. Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010;8:836-48.
40. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-4.
41. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomized study. Curr Med Res Opin 2006;22:873-83.
42. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol 2007;47:135-41.
43. De Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: A metaanalysis. Pharmacotherapy 2004;24:584-91.
44. Browning JD. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study Hepatol 2006;44:466-71.
45. Cohen DE, Anania FA, Chalassani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C.
46. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3polyunsaturated fatty acids in subjects with non-alcoholic fatty liver disease. Dig Liv Dis 2008;40:194-9.
47. Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seals on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395-400.
48. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 2004;39:770-8.
49. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43.
50. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo controlled trial. Hepatology 2010;52:472-9.
51. Ratziu V, Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011-9.
52. Kleiner DE, Brunt EM, Van Natta M, et al; for the Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
53. Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol 2010;53:719-23.
54. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: High-dose vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
55. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men, the Physician's Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
56. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: Review of the evidence of efficacy. Clin Gastroenterol Hepatol 2007;5:408-16.
57. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-43.
58. Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial. Hepatol 2009;50:1818-26.
59. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005;21:702-7.
60. Adams LA, Zein CO, Angulo P, Lindor KD: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8.
61. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation inpatients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:634-8.
62. Valenti L, Fracanzani AI, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterology 2010;138:905-12.
63. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-55.
64. Day C, James O. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5.
65. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. Liver 2001;21:295-9.
66. Anderson GJ, Ramm GA, Halliday JW, Powell LW. Ferritin metabolism in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis. London: Cambridge University Press, 2000:145-56.
67. Valenti L, Fracanzani AI, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with non-alcoholic fatty liver disease and hyperferritinemia: Evidence from a case-control study. Am J Gastroenterol 2007;102:1251-8.
68. Valenti L, Fracanzani AL, Fargion S, et al. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003;124:866-7.
69. Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
70. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterol 2009;137:532-40.
71. Dallal RM, Mattar SG, Lord JL, et al. Results of laproscopic gastric bypass in patients with cirrhosis. Obes Surg 2004;14:47-53.
72. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;1:CD007340.
73. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-6.
74. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;15;(6):CD003619
75. 〈www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm〉 (Accessed September 1, 2011).
76. Hézode C, Castéra L, Roudot-Thoraval F et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011;34:656-63.
77. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009;50:1072-8.